Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/refractory AL Amyloidosis ...

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis ...

– Patient enrollment exceeding expectations –

Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming

NXC-201 trial expands to 14 centers amid strong enrollment. Memorial Sloan-Kettering lead investigator to present interim data at ASCO 2025. Learn trial timeline.

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - IMMIX BIOPHARMA INC

Immix Biopharma today reported ASCO abstract results from its U.S. multi-center NEXICART-2 Phase 1/2 clinical trial of NXC-201 demonstrating strong efficacy and favorable safety. – NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) – – No relapses recorded to-date; no safety signals identified – – Updated results with a later data cutoff, including endpoint analysis, will be presented at ASCO by lead investigator Heather La…